Alerce Investment Management, L.P. (“Alerce Management”), a Delaware limited partnership and a registered investment adviser, expects to provide investment advisory services to investment funds privately offered to qualified investors in the United States and elsewhere. Alerce Management, formerly known as Satter Management Co., L.P., commenced operations in November 2016. Each of Satter Medical Technology GP, L.P., Alerce Medical Technology GP, L.P. and SRX Investment GP, L.P. (each, a “General Partner” and together with Alerce Management and their affiliated entities, “Alerce Management Group”) is an affiliated advisory entity subject to the Advisers Act pursuant to Alerce Management’s registration in accordance with SEC guidance. This Brochure also describes the business practices of the General Partners, which, together with Alerce Management, operate as a single advisory business. Alerce Management Group is controlled by Muneer A. Satter (the “Principal”). Alerce Management provides investment advisory services to its clients, including Alerce Medical Technology Partners, L.P. (“Alerce Medical”), Satter Medical Technology Partners, L.P. (“SMTP”), SMTP Co-Invest I, L.P. (“Co-Invest Fund”), SMTP Co-Invest II (AWC), L.P. (“Co- Invest II Fund”), SRX Investment, L.P. (“SRX”) and SRX Investment II, L.P. (“SRX II”). Each of Co-Invest Fund, Co-Invest II Fund, SRX and SRX II is an entity formed to facilitate an investment (or co-investment) in a single portfolio company. Alerce Medical, SMTP, Co-Invest Fund, Co-Invest II Fund, SRX and SRX II, together with any future private investment fund to which Alerce Management or its affiliates provide investment advisory services, are referred to herein as the “Funds”. Alerce Management also provides investment advisory services to certain accounts of persons and entities (mostly Satter family entities) affiliated with the Principal (the “Principal Group,” and any Fund owned primarily by the Principal Group, the “Principal Group Fund”) with respect to those assets of such Principal Group accounts invested in securities within the medical technology sector (and, including such other assets, from time to time, as are invested alongside, in conjunction with or otherwise with a Fund in a portfolio company in which such Fund makes or has made an investment). The Funds are private equity funds that will invest in both privately held and publicly traded operating entities, generally referred to herein as “portfolio companies.” Alerce Management Group’s investment advisory services to the Funds consist of identifying and evaluating investment opportunities, negotiating the terms of investments, managing and monitoring investments and achieving dispositions for such investments. From time to time, the Principal or other personnel of Alerce

Management Group or its affiliates generally serve on such portfolio companies’ respective boards of directors or otherwise act to influence control over management of the companies in which the Funds have invested. Please see “Conflicts of Interest” in Item 8, Methods of Analysis, Investment Strategies, and Risk of Loss for a discussion of the conflicts of interest arising from this arrangement. Alerce Management Group’s advisory services for the Funds are detailed in the applicable private placement memoranda or other offering documents (each, a “Memorandum”), limited partnership or other operating agreements or governing documents (each, a “Partnership Agreement”) and are further described below under “Methods of Analysis, Investment Strategies and Risk of Loss.” Investors in the Funds (generally referred to herein as “investors” or “limited partners”) participate in the overall investment program for the applicable Fund, but in certain circumstances are excused from or have an investment percentage vary for a particular investment due to legal, regulatory or other agreed-upon circumstances pursuant to the relevant Partnership Agreement; such arrangements generally do not and will not create an adviser-client relationship between Alerce Management Group and any investor. The General Partner has established an advisory board for each of Alerce Medical and SMTP (and generally expects, but is not obligated to, establish an advisory board with respect to Funds formed in the future) comprised of limited partners thereof selected by the General Partner (any such board, an “Advisory Board”). As described herein and in the relevant Partnership Agreement, the applicable Advisory Board will provide such advice and counsel as is requested by the General Partner in connection with Fund investments, potential conflicts of interest and other Fund matters. The Funds or the General Partner are permitted to enter into side letters or other similar agreements (“Side Letters”) with certain investors that have the effect of establishing rights (including economic or other terms) under, or altering or supplementing the terms of, the relevant Partnership Agreement with respect to such investors. Additionally, as described herein and in the relevant Memorandum and as permitted by the relevant Partnership Agreement, Alerce Management Group expects to provide (or agrees to provide) co-investment opportunities (including the opportunity to participate in co-invest vehicles) to certain investors or other persons, including the Principal Group Fund. As of December 31, 2023, Alerce Management managed approximately $161,918,985 in client assets on a discretionary basis. Satter Management Co. GP, LLC, a Delaware limited liability company, acts as the general partner of Alerce Management.